SG146681A1 - 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) - Google Patents
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)Info
- Publication number
- SG146681A1 SG146681A1 SG200807148-2A SG2008071482A SG146681A1 SG 146681 A1 SG146681 A1 SG 146681A1 SG 2008071482 A SG2008071482 A SG 2008071482A SG 146681 A1 SG146681 A1 SG 146681A1
- Authority
- SG
- Singapore
- Prior art keywords
- cml
- treatment
- myelogenous leukemia
- chronic myelogenous
- quinolinecarbonitriles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51781903P | 2003-11-06 | 2003-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG146681A1 true SG146681A1 (en) | 2008-10-30 |
Family
ID=34590192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200807148-2A SG146681A1 (en) | 2003-11-06 | 2004-11-03 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
Country Status (18)
Country | Link |
---|---|
US (2) | US7417148B2 (no) |
EP (1) | EP1680119A1 (no) |
JP (1) | JP2007533655A (no) |
KR (1) | KR20060118461A (no) |
CN (1) | CN1874776A (no) |
AU (1) | AU2004289243B2 (no) |
BR (1) | BRPI0416289A (no) |
CA (1) | CA2543163A1 (no) |
CO (1) | CO5690608A2 (no) |
CR (1) | CR8350A (no) |
EC (1) | ECSP066548A (no) |
IL (1) | IL175424A0 (no) |
MX (1) | MXPA06004744A (no) |
NO (1) | NO20062255L (no) |
RU (1) | RU2006113691A (no) |
SG (1) | SG146681A1 (no) |
WO (1) | WO2005046693A1 (no) |
ZA (1) | ZA200603596B (no) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG146681A1 (en) * | 2003-11-06 | 2008-10-30 | Wyeth Corp | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
MX2007016230A (es) * | 2005-06-17 | 2008-03-06 | Univ Texas | Inhibicion de lesiones osteoliticas mediante inhibidores de quinasa src. |
BRPI0611977A2 (pt) * | 2005-06-24 | 2010-10-13 | Wyeth Corp | uso de um composto |
WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
WO2008060283A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
US11103497B2 (en) * | 2007-06-01 | 2021-08-31 | Wyeth Llc | Treatment of imatinib resistant leukemia |
WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
WO2015123758A1 (en) | 2014-02-20 | 2015-08-27 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
US20180000771A1 (en) | 2015-01-13 | 2018-01-04 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
WO2020209843A1 (en) | 2019-04-09 | 2020-10-15 | Massachusetts Institute Of Technology | A micro physiological model for neuronal and muscular diseases and disorders |
WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
TW200423938A (en) * | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
SG146681A1 (en) * | 2003-11-06 | 2008-10-30 | Wyeth Corp | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
-
2004
- 2004-11-03 SG SG200807148-2A patent/SG146681A1/en unknown
- 2004-11-03 US US10/980,097 patent/US7417148B2/en active Active
- 2004-11-03 CA CA002543163A patent/CA2543163A1/en not_active Abandoned
- 2004-11-03 KR KR1020067008812A patent/KR20060118461A/ko not_active Application Discontinuation
- 2004-11-03 JP JP2006539641A patent/JP2007533655A/ja active Pending
- 2004-11-03 EP EP04800721A patent/EP1680119A1/en not_active Withdrawn
- 2004-11-03 CN CNA2004800323110A patent/CN1874776A/zh active Pending
- 2004-11-03 BR BRPI0416289-7A patent/BRPI0416289A/pt not_active Application Discontinuation
- 2004-11-03 AU AU2004289243A patent/AU2004289243B2/en not_active Expired
- 2004-11-03 WO PCT/US2004/036722 patent/WO2005046693A1/en active Application Filing
- 2004-11-03 RU RU2006113691/14A patent/RU2006113691A/ru unknown
- 2004-11-03 MX MXPA06004744A patent/MXPA06004744A/es active IP Right Grant
-
2006
- 2006-04-20 CR CR8350A patent/CR8350A/es not_active Application Discontinuation
- 2006-05-04 IL IL175424A patent/IL175424A0/en unknown
- 2006-05-05 EC EC2006006548A patent/ECSP066548A/es unknown
- 2006-05-05 ZA ZA200603596A patent/ZA200603596B/xx unknown
- 2006-05-19 NO NO20062255A patent/NO20062255L/no not_active Application Discontinuation
- 2006-05-26 CO CO06051033A patent/CO5690608A2/es not_active Application Discontinuation
-
2008
- 2008-06-16 US US12/139,834 patent/US7919625B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ZA200603596B (en) | 2009-12-30 |
KR20060118461A (ko) | 2006-11-23 |
AU2004289243A1 (en) | 2005-05-26 |
AU2004289243B2 (en) | 2010-07-22 |
NO20062255L (no) | 2006-08-01 |
IL175424A0 (en) | 2008-04-13 |
JP2007533655A (ja) | 2007-11-22 |
US7417148B2 (en) | 2008-08-26 |
US20100029677A1 (en) | 2010-02-04 |
US7919625B2 (en) | 2011-04-05 |
MXPA06004744A (es) | 2006-07-05 |
CR8350A (es) | 2006-10-06 |
ECSP066548A (es) | 2006-10-17 |
WO2005046693A1 (en) | 2005-05-26 |
EP1680119A1 (en) | 2006-07-19 |
CN1874776A (zh) | 2006-12-06 |
BRPI0416289A (pt) | 2007-01-23 |
RU2006113691A (ru) | 2007-12-20 |
US20050101780A1 (en) | 2005-05-12 |
CO5690608A2 (es) | 2006-10-31 |
CA2543163A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062255L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) | |
EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
EA200601847A1 (ru) | Замещённые метиларил- или гетероариламидные соединения | |
SI1585739T1 (sl) | Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze | |
CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
MXPA04000411A (es) | Tiazolidinonas arilo sustituidas y uso de las mismas. | |
AU2006325931A8 (en) | Amine compound and use thereof for medical purposes | |
IL117875A0 (en) | Pharmaceutical compositions for inhibiting th growth of cancers | |
WO2004071388A3 (en) | Medicinal compounds | |
CA2503451A1 (en) | Heterocyclic compounds and antitumor agent comprising the same as effective component | |
DE60236719D1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
TW200727893A (en) | Methods for treating sexual dysfunction | |
HK1085675A1 (en) | Anticancer compounds | |
DK1181299T3 (da) | C-2-modificerede erythromycinderivater | |
BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
MXPA05008706A (es) | 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas. | |
WO2005046672A3 (fr) | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose | |
MY136824A (en) | Substituted benzoxazinones and uses thereof | |
TW200714593A (en) | Agent for treatment of solid tumor | |
MY158003A (en) | Antibacterial 3',5-disubtituted 2,4'-dihydroproxybiphenyl compounds, derivatives and related methods | |
MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
TW200510384A (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
WO2008059130A9 (fr) | Thionucléosides et applications pharmaceutiques |